Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19
https://doi.org/10.37489/2588-0519-2020-S4-53-59
Abstract
Taking recent publications into account, one should consider avoiding routine use of hydroxychloroquine, especially if combined with azithromycin, for COVID-19. Such treatment may be associated with the increased risk for hospital mortality and QT prolongation, while there is no documented effectiveness regarding SARS-CoV-2 clearance and outcomes. This treatment may be considered in individual cases, provided potential benefit and risks are carefully weighted, and safety monitoring is enhanced. Hydroxychloroquine safety in outpatients with COVID-19 is poorly studied and risks are increased by challenges in monitoring QT and electrolytes, hence hydroxychloroquine cannot be considered as first line treatment in outpatient settings. Such use of hydroxychloroquine is not recommended if clinical, instrumental, and laboratory monitoring are not in place.
About the Authors
V. A. Otdelenov
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Otdelenov Vitaly A. – Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8357-5770
Moscow
Yu. Yu. Kiselev
Oslo Metropolitan University
Norway
Norway
Kiselev Yuri Yu. – PhD, Associate Professor at the Faculty of Health Sciences OsloMet
Oslo
K. B. Mirzaev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Mirzaev Karin B. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8308-7599
Moscow
A. V. Matveev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Matveev Alexander V. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8518-1320
Moscow
D. A. Sychev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head. Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556
Moscow
References
1. State register of medicines. Query «hydroxychloroquine», search by INN. (In Russ). URL: https://grls.rosminzdrav.ru/grls.aspx?s=гидроксихлорохин&m=mnn (accessed: 24.05.2020).
2. State register of medicines. Plaquenil. Instructions for medical use. (In Russ). URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=dd41b667c371-45bb-b9d0-f7053eab7c3d&t= (accessed: 17.05.2020).
3. Yao X. et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Jul 28;71(15):732-739. DOI: 10.1093/cid/ciaa237
4. Vincent MJ et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005 Aug 22;2:69. DOI: 10.1186/1743-422X-2-69
5. Keyaerts E et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8. DOI: 10.1016/j.bbrc.2004.08.085
6. Devaux CA et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 May;55(5):105938. DOI: 10.1016/j.ijantimicag.2020.105938
7. Sahraei Z et al. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents. 2020 Apr;55(4):105945. DOI: 10.1016/j.ijantimicag.2020.105945
8. Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670. DOI: 10.1093/jac/dkaa114
9. Coronavirus (COVID-19) Update: FDA Reiterates Importance of Close Patient Supervision for ‘Off-Label’ Use of Antimalarial Drugs to Mitigate Known Risks, Including Heart Rhythm Problems [Electronic resource]. URL: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-reiterates-importance-close-patientsupervision-label-use (accessed: 24.05.2020).
10. Temporary guidelines of the Ministry of health of the Russian Federation for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 6 (28.04.2020). (In Russ). Доступно по: https://static-1.rosminzdrav.ru/system/attachments/attaches/000/050/116/original/28042020_МR_COVID-19_v6.pdf Ссылка активна на 25.05.2020
11. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Electronic resource]. URL: https://www.covid19treatmentguidelines.nih.gov/ (accessed: 25.05.2020).
12. UW Medicine COVID-19 Resource Site [Electronic resource] // University of Washington. 2020. URL: https://covid-19.uwmedicine.org/Pages/default.aspx (accessed: 25.05.2020).
13. Tang W et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. MedRxiv. 2020. DOI: 10.1101/2020.04.10.20060558
14. Mahevas M et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. MedRxiv. April 14, 2020. DOI: 10.1101/2020.04.10.20060699
15. Brigham and Women’s Hospital COVID-19 Clinical Guidelines [Electronic resource]. URL: https://covidprotocols.org/ (accessed: 25.05.2020).
16. Colleges C.A.M. and N. National COVID-19 Clinical Evidence Taskforce [Electronic resource]. 2020. P. Guidelines. URL: https://covid19evidence.net.au/ (accessed: 25.05.2020).
17. Coronavirus (COVID-19): latest guidance for medicines safety — GOV.UK [Electronic resource]. URL: https://www.gov.uk/drugsafety-update/coronavirus-covid-19-latest-guidance-for-medicinessafety#chloroquine-and-hydroxychloroquine (accessed: 25.05.2020).
18. Search of: Hydroxychloroquine treatment | COVID-19 — List Results — ClinicalTrials.gov [Electronic resource]. URL: https://clinicaltrials.gov/ct2/results?term=Hydroxychloroquine+treatment&cond=COVID-19&Search=Apply&age_v=&gndr=&type=&rslt= (accessed: 25.05.2020).
19. Mehra MR et al. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020 May 22;S0140-6736(20)31180-6. DOI: 10.1016/S0140-6736(20)31180-6
20. Singh AK et al. “Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.”. Diabetes Metab Syndr. Jul-Aug 2020;14(4):589-596. DOI: 10.1016/j.dsx.2020.05.017
21. Gérard A et al. “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapie. Jul-Aug 2020;75(4):371-379. DOI: 10.1016/j.therap.2020.05.002
22. FDA Drug Safety Communication: FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. URL: https://www.fda.gov/media/137250/download (accessed: 25.05.2020).
23. HRS COVID-19 Task Force Update: April 21, 2020 URL: https://www.hrsonline.org/COVID19-Challenges-Solutions/hrscovid-19-task-force-update-april-21-2020 (accessed: 25.05.2020).
24. Timothy F. Simpson, MD, PharmD; Richard J. Kovacs, MD, FACC; and Eric C. Stecker, MD, MPH, FACC. American College of Cardiology. https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycintreatment-for-covid-19 (accessed: 25.05.2020).
25. Giudicessi JR et al. Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19). Mayo Clin Proc. 2020 Jun;95(6):1213-1221. DOI: 10.1016/j.mayocp.2020.03.024
26. Jordan M Prutkin, MD, Bradley P Knight, Brian C Downey. Coronavirus disease 2019 (COVID-19): Arrhythmias and conduction system disease. https://www.uptodate.com/contents/coronavirusdisease-2019-covid-19-arrhythmias-and-conduction-systemdisease#H3480858110 (accessed: 25.05.2020).
Review
For citations:
Otdelenov V.A., Kiselev Yu.Yu., Mirzaev K.B., Matveev A.V., Sychev D.A. Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2020;(4S):53-59. (In Russ.) https://doi.org/10.37489/2588-0519-2020-S4-53-59
Views:
1125
Email this article 